Shares of Relmada Therapeutics, Inc. (RLMD) are down over 70%, following disappointing outcome of interim analysis of its Phase 3 Reliance II trial.
Reliance II is a phase III trial designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder (MDD), to be used in combination with other approved anti-depressants.
An Independent Data Monitoring Committee (DMC), which conducted the interim analysis, has found that trial is unlikely to meet the primary efficacy endpoint with statistical significance.
Relmada will evaluate the full dataset to determine the next steps for the REL-1017 program.
RLMD closed Tuesday's trading at $2.77, down 15.81 %. In premarket trading today, the stock is down by 74.72 % at $0.70
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.